Provided is a method of diagnosing or treating a disease in a subject using the vesicles derived from bacteria of the genus Rhodococcus. The vesicles are significantly decreased in a clinical sample obtained from a patient with lung cancer, pancreatic cancer, bile duct cancer, breast cancer, bladder cancer, lymphoma, diabetes, stroke, myocardial infarction, asthma, COPD, and dementia, compared with a normal individual, and administration of the vesicles to the patient inhibits the secretion of inflammation mediators caused by pathogenic vesicles such as E. coli-derived vesicles, and inhibits cranial nerve cell damage caused by stress hormones, therefore the vesicles are used in a method of diagnosing lung cancer, pancreatic cancer, bile duct cancer, breast cancer, bladder cancer, lymphoma, diabetes, stroke, myocardial infarction, asthma, COPD, and/or dementia, and a method of alleviating or treating a malignant disease, diabetes, stroke, a cardiovascular disease, an inflammatory pulmonary disease, and/or a cranial nerve disease.

Liposomal topical compositions containing phenolic anti-inflammatory agents, and methods for making thereof, are presented. These compositions are generally used for helping to prevent solar radiation-induced skin damage and helping to prevent and/or treat inflammatory dry skin conditions caused by eczema and contact dermatitis.

Liposomal topical compositions containing phenolic anti-inflammatory agents, and methods for making thereof, are presented. These compositions are generally used for helping to prevent solar radiation-induced skin damage and helping to prevent and/or treat inflammatory dry skin conditions caused by eczema and contact dermatitis.

The present invention provides new peptides useful as skin whitening agents and their uses in cosmetic or therapeutic applications.

The present invention provides new peptides useful as skin whitening agents and their uses in cosmetic or therapeutic applications.

A method of producing yeast-polyphenol ferment extract includes growing the cells of a yeast of pichia genus in a growth media to late-logarithmic growth phase, in which the carbon source in the media is exhausted; exposing the cells to a non-cytotoxic dose of polyphenol; and extracting cytoplasmic and extra-cellular components of the exposed yeast cells from the growth media.

A method of producing yeast-polyphenol ferment extract includes growing the cells of a yeast of pichia genus in a growth media to late-logarithmic growth phase, in which the carbon source in the media is exhausted; exposing the cells to a non-cytotoxic dose of polyphenol; and extracting cytoplasmic and extra-cellular components of the exposed yeast cells from the growth media.

An illuminating complex for enhancing beauty includes at least one of yangu seed oil, baobab seed oil, mafura butter (trichilia oil), dipotassium glycyrrhizinate, alpha-arbutin, and a structure forming agent. A pore refining complex includes at least one of kalahari melon seed oil, grapeseed oil, rooibos tea, an extract blend of at least one of witch hazel, white willow bark, acacia senegal, papaya seed, and lemongrass, and a structure forming agent. The structure forming agent preferably comprises at least one of an emulsification, an encapsulation, and liposomes.

An illuminating complex for enhancing beauty includes at least one of yangu seed oil, baobab seed oil, mafura butter (trichilia oil), dipotassium glycyrrhizinate, alpha-arbutin, and a structure forming agent. A pore refining complex includes at least one of kalahari melon seed oil, grapeseed oil, rooibos tea, an extract blend of at least one of witch hazel, white willow bark, acacia senegal, papaya seed, and lemongrass, and a structure forming agent. The structure forming agent preferably comprises at least one of an emulsification, an encapsulation, and liposomes.

The present invention relates to vesicular formulations for use in the topical administration of a therapeutic, metabolic, cosmetic or structural Agent Of Interest (“AOI”) and methods of administering an AOI.